Skip to main content
TipRanks
Go Ultimate75% OFF

Ocular Therapeutix (0OT) Q3 2026 Earnings Report

5 Followers

DE:0OT Q3 2026 EPS Results

Actual EPS
-EUR 0.38
Consensus EPS
-EUR 0.33
Beat/Miss
Missed by -EUR 0.05
One Year Ago EPS
-EUR 0.34

DE:0OT Q3 2026 Revenue Results

Actual Revenue
EUR 11.60M
Expected Revenue
EUR 12.86M
Beat/Miss
Missed by -EUR 1.26M
YoY Revenue Growth
-11.48%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/09/2026
Time
Before Open
Conference Call
Monday, November 9, 2026
DE:0OT Upcoming Earnings

Ocular Therapeutix's next earnings date is estimated for March 8, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:0OT Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 09, 2026|% Change Since:-5.22%|
Earnings Call Sentiment|Positive

The call was strongly positive, driven by landmark SOL-1 superiority results, reported durability of up to 12 months, continued confidence in SOL-R, an NDA submission planned for the fourth quarter of 2026, a potentially expedited 505(b)(2) pathway, and extensive commercial preparation. The principal negative points were that AXPAXLI remains unapproved, SOL-R efficacy results will not be available until the first quarter of 2028, a subset of patients was excluded during screening, and the cash runway estimate excludes full commercialization expenses.

Company Guidance

Ocular remains on track to submit its NDA for AXPAXLI in wet AMD in the fourth quarter of this year, with a safety database including more than 300 patients with at least 1 year follow-up after AXPAXLI treatment, and expects the 505(b)(2) pathway to shorten the review time line by up to 60 days; SOL-R’s interim safety analysis remains planned for this quarter, its primary endpoint is week 40, key secondary endpoints remain at week 56 and 96, the study will remain masked through week 96, and top line results remain on track for the first quarter of 2028. SOL-X is modifying dosing from 24-week treatment intervals to 48-week treatment intervals, while HELIOS-3 is evaluating once yearly AXPAXLI; Ocular ended the third quarter with $530.6 million in cash and cash equivalents, providing an expected runway into 2028, based on our current assumptions, but excluding the full anticipated expenses of commercializing AXPAXLI.

  • Landmark SOL-1 Phase III Superiority ResultsOcular reported landmark Phase III superiority results for AXPAXLI in SOL-1. Approximately 75% of AXPAXLI-treated patients maintained vision at the week 36 primary endpoint and approximately two-thirds maintained vision through week 52 after a single injection, despite the trial enrolling a challenging population specifically selected to lose vision.
  • Long-Duration Disease Control and DrynessIn a post-hoc SOL-R analysis, approximately 71% of AXPAXLI-treated subjects were quantitatively dry at week 8 using a stringent definition of less than or equal to 10 nanoliters of total retinal fluid. Approximately 70% of those subjects remained quantitatively dry through week 36 after a single injection.
  • Strong Durability and Rescue-Free ResultsManagement stated that two-thirds of patients in SOL-1 were rescue-free at month 12 following a single AXPAXLI injection. The company said SOL-1 demonstrated 9- to 12-month durability and supported confidence in longer treatment intervals.
  • Planned Wet AMD NDA Submission Remains on TrackOcular remains on track to submit its NDA for AXPAXLI in wet AMD in the fourth quarter of 2026 following a positive pre-NDA meeting with the FDA in September. The planned submission will include SOL-1 week 52 efficacy data, SOL-1 and interim SOL-R week 52 safety data, repeat-dosing safety data, and other confirmatory evidence.
  • Broad Safety Database and Repeat-Dosing EvidenceThe safety database at the time of submission is expected to include more than 300 patients with at least one year of follow-up after AXPAXLI treatment, consistent with FDA requirements. Management stated that all more than 300 patients included in the regulatory safety package will have received repeat dosing.
  • Potentially Faster 505(b)(2) Regulatory PathwayOcular remains aligned with the FDA on pursuing approval through the 505(b)(2) pathway, which management said has the potential to shorten the review timeline by up to 60 days compared with the traditional 505(b)(1) pathway for a new molecular entity.
  • SOL-R Design and Confidence in SuccessSOL-R includes a six-month screening and loading period intended to exclude patients with early persistent fluid or significant fluid variability before randomization. Management said this design selects a population in which SOL-1 showed the strongest durability profile and that confidence in SOL-R continues to grow.
  • SOL-R Primary Endpoint Change Preserves Trial IntegrityOcular proactively moved the SOL-R primary efficacy endpoint from week 56 to week 40 so that all patients would complete their primary efficacy assessment before the planned interim safety analysis. Management said week 40 exceeds the FDA's minimum 36-week requirement, preserves the week 56 and week 96 secondary endpoints, and results in only a minimal statistical alpha penalty of 0.0001.
  • Long-Term SOL-R Data Remains ProtectedSOL-R will remain masked through week 96, with topline results on track for the first quarter of 2028. The study is intended to provide repeat-dosing data for every-six-month treatment, longer-term safety information, superiority data against aflibercept 8 milligrams, and evaluations of fibrosis and atrophy.
  • SOL-X Extended to Annual Dosing IntervalsBased on the up to 12-month durability observed in SOL-1, Ocular is modifying SOL-X dosing intervals from 24 weeks to 48 weeks. The company said SOL-X is intended to generate evidence supporting potential annual AXPAXLI maintenance dosing and evaluate whether earlier treatment may reduce fibrosis and atrophy and improve long-term visual outcomes.
  • Differentiated Drug and Delivery ApproachManagement highlighted axitinib's potency, stating that it has approximately 100-fold greater potency against VEGF receptor 2 than vorolanib and greater potency against other VEGF receptors. Ocular also stated that its bioresorbable hydrogel delivers consistent daily axitinib release and that human SOL-1 durability was consistent with preclinical findings.
  • Large Maintenance-Treatment Commercial OpportunityManagement stated that maintenance treatment represents more than 90% of the wet AMD treatment market and that more than 40% of patients are lost to therapy in the first year under frequent bolus dosing. Following the discontinuation of a peer's pure TKI program, Ocular said AXPAXLI has no direct late-stage intravitreal sustained-release competitor.
  • Commercial and Payer PreparationOcular continues to invest in commercial infrastructure, market access, and launch execution. Its payer team has conducted or is advancing pre-approval information exchange discussions with 100% of its top-priority national and regional payer accounts, covering roughly 84% of commercial lives.
  • Expansion into Diabetic Retinal DiseaseEnrollment continues in HELIOS-3, a Phase III study evaluating once-yearly AXPAXLI across diabetic retinal disease, including patients with non-center-involving diabetic macular edema. Management highlighted an estimated 6.3 million people with vision-threatening non-proliferative diabetic retinopathy in the United States, with less than 1% currently treated.
  • Board Strengthened for Commercial ExecutionDr. Riad Sherif joined Ocular's Board of Directors, while Dr. Seung Suh Hong will retire at the end of 2026. Management cited Dr. Sherif's ophthalmology, global commercial, and organizational leadership experience as a strategic addition during the company's planned transition toward commercialization.
  • Solid Cash PositionOcular ended the third quarter with $530.6 million in cash and cash equivalents. Management expects this to provide a runway into 2028 based on current assumptions, while noting that the estimate excludes the full anticipated expenses of commercializing AXPAXLI.

DE:0OT Earnings History

DE:0OT earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 08, 20272026 (Q4)-0.39--0.26――
Nov 09, 20262026 (Q3)-0.33-0.38-0.34-10.53% (-0.04)
Aug 03, 20262026 (Q2)-0.36-0.32-0.3510.26% (+0.04)
May 05, 20262026 (Q1)-0.28-0.36-0.34-5.26% (-0.02)
Feb 05, 20262025 (Q4)-0.29-0.26-0.260.00% (+0.00)
Nov 04, 20252025 (Q3)-0.34-0.34-0.2-72.73% (-0.14)
Aug 05, 20252025 (Q2)-0.32-0.35-0.23-50.00% (-0.12)
May 05, 20252025 (Q1)-0.26-0.34-0.4422.45% (+0.10)
Mar 03, 20252024 (Q4)-0.23-0.26-0.3217.14% (+0.05)
Nov 14, 20242024 (Q3)-0.22-0.20-0.01-3566.67% (-0.19)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed